Monoclonal antibodies market to hit $804.7 billion by 2033

The global monoclonal antibodies market is projected to reach USD 804.7 billion by 2033, growing at a 12.5% CAGR from 2024. North America is expected to hold 47.5% market share in 2024, driven by advancements in oncology treatments, particularly immune checkpoint inhibitors. Major companies include Roche, Novartis, and Pfizer, alongside specialized startups like Genentech and Amgen, enhancing product development through strategic alliances.